首页> 外文期刊>American Journal of Ophthalmology: The International Journal of Ophthalmology >Behet disease: Visual prognosis and factors influencing the development of visual loss
【24h】

Behet disease: Visual prognosis and factors influencing the development of visual loss

机译:Behet疾病:视觉预后和影响视力丧失发展的因素

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To assess the visual prognosis of patients with ocular Behet disease and to determine factors predictive of visual loss and severe visual loss. Design: Retrospective case series. Methods: One hundred seventy-five eyes of 107 patients diagnosed with ocular Behet disease were included. The main outcome measures were visual loss (best-corrected visual acuity, worse than 20/40) and severe visual loss (best-corrected visual acuity, 20/200 or worse). Results: The mean duration of follow-up was 6.5 years. Presenting visual acuity was worse than 20/40 in 50% of eyes and 20/200 or worse in 21% of eyes; approximately one third of this was reversible with treatment. The most common cause of irreversible severe visual loss was ischemic maculopathy. At 10 years, there was a 39% risk of visual loss and a 24% risk of severe visual loss, the latter figure being reduced to 13% if patients with irreversible visual loss at presentation were excluded. After controlling for potentially confounding variables, male sex, unilateral disease, and left eye involvement all were statistically significant risk factors for severe visual loss at 5 and 10 years. Patients who were treated with biologic agents were less likely to have severe visual loss in either eye at both 5 and 10 years. Conclusions: Many patients with ocular Behet disease still have irreversible visual loss at presentation. However, the visual prognosis is otherwise improved, with a 10-year risk of severe visual loss of 13% in this cohort. The use of biologic agents is associated with a lower risk of severe visual loss at 5 and 10 years.
机译:目的:评估眼Behet病患者的视觉预后,并确定可预测视力丧失和严重视力丧失的因素。设计:回顾案系列。方法:纳入107例被诊断为眼Behet病的患者的175只眼。主要结局指标为视力丧失(最佳矫正视力,低于20/40)和严重视力丧失(最佳矫正视力,20/200或更差)。结果:平均随访时间为6.5年。在50%的眼睛中呈现视力低于20/40,在21%的眼睛中呈现20/200或更低;其中约三分之一可逆转治疗。不可逆的严重视力丧失的最常见原因是缺血性黄斑病变。在10年时,有39%的视力丧失风险和24%的严重视力丧失风险,如果排除出现时不可逆视力丧失的患者,则后者的数字降至13%。在控制了可能造成混淆的变量之后,男性,单侧疾病和左眼受累都是在5年和10年时严重视力丧失的统计学上显着的危险因素。用生物制剂治疗的患者在5年和10年时两只眼睛的严重视力丧失的可能性均较小。结论:许多Behet眼病患者在出现时仍存在不可逆的视力丧失。但是,视力预后得到了改善,在该人群中有10年严重视力丧失的风险为13%。使用生物制剂与5岁和10岁时严重视力丧失的风险较低有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号